Champions Oncology, Inc. — FY2024 Form 10-K
Reporting period: Fiscal year ended April 30, 2024; comparisons are with the year ended April 30, 2023. The company provides oncology research services and also develops SaaS tools and early-stage therapeutic programs. Research services are its primary revenue source.
Financial results and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $50.2 million | $53.9 million |
| Gross profit / gross margin | $20.8 million / 41% | $24.3 million / 45% |
| Operating loss | $7.4 million | $5.3 million |
| Net loss | $7.3 million | $5.3 million |
| Net loss per share | $0.54 | $0.39 |
| Cash from operating activities | $(6.1) million | $4.0 million provided |
| Cash from investing activities | $(0.8) million | $(2.9) million |
| Cash from financing activities | $(0.5) million | $0.01 million provided |
- Cash fell to $2.6 million from $10.1 million. Current assets were $13.6 million versus current liabilities of $21.5 million, a $7.9 million working-capital deficit.
- Total liabilities were $28.0 million; stockholders’ equity was negative $1.9 million. The filing reports no off-balance-sheet debt. Lease obligations included $7.4 million of operating lease liabilities and $0.4 million of finance lease payments.
- Deferred revenue was $12.1 million, down from $12.8 million. Net accounts receivable, including unbilled services, was $9.5 million.
Changes and notable items
- Revenue declined 6.9%, attributed primarily to study cancellations in FY2023 and slower bookings expansion, which reduced available revenue in FY2024.
- Gross margin fell to 41% from 45% as costs remained relatively steady despite lower revenue; the company cited operational inefficiencies and higher mouse and laboratory-supply costs.
- Research and development expense decreased 17.3% to $9.5 million, reflecting cost reductions, maturing platforms and lower drug-discovery spending. General and administrative expense rose 8.1% to $11.1 million, including higher compensation, recruiting, stock compensation and credit-loss reserves.
- FY2024 included a $435,000 loss on disposal of laboratory equipment. FY2023 included an $807,000 impairment charge on Lumin software; no impairment was recorded in FY2024.
- The company repurchased 105,911 shares for $634,000 during FY2024. Cumulative repurchases under its $5.0 million authorization were about $708,000 as of April 30, 2024.
Outlook, risks and contingencies
- Going concern: Management and the independent auditor identify substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, operating cash outflow, limited cash and the working-capital deficit. The auditor’s report is not qualified, but includes a going-concern emphasis. The financial statements contain no adjustments for a possible inability to continue operations.
- The company says it may need to raise equity or debt capital in the near term, but gives no assurance that financing will be available or acceptable. It warns that inability to obtain financing could require reorganization, including under bankruptcy or insolvency laws.
- Management discusses possible strategies to increase revenue and reduce costs, but provides no quantified revenue, earnings or cash-flow guidance. Strategic options for the drug-discovery business may include a spin-out or capital raise.
- Key business risks include cancellations or changes to customer studies, intense competition, reliance on research services, early-stage drug-development uncertainty, regulatory and laboratory requirements, dependence on specialized personnel, and the need to protect proprietary know-how. One customer represented 10% of FY2024 revenue and 12% of receivables at year-end.
- The auditor identified revenue recognition as a critical audit matter because estimating progress toward completion of research-service projects requires management judgment. No material litigation was reported. The company also disclosed $362,000 of royalty expense in FY2024 under tumor-model licensing arrangements.
Important facts for investors to verify
- Cash runway and near-term financing plans, including the availability, timing, terms and dilution impact of any capital raise.
- Whether bookings, cancellations and customer study activity are improving enough to restore revenue growth and gross margin.
- Drivers of laboratory inefficiency and higher mouse and supply costs, and whether corrective actions are reducing them.
- Progress and commercial prospects for Lumin and the early-stage drug-discovery pipeline, including any strategic transactions.
- Project-completion estimates supporting revenue recognition, receivables collectability and the concentration of revenue and receivables with major customers.